Jiachun Su
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiachun Su has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Zhewei Sun
Shanghai Institute of Infectious Disease and Biosecurity, Huashan Hospital, Fudan University Shanghai, PR China; Institute of Antibiotics, Huashan Hospital, Fudan University Shanghai, PR China; Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of the People's Republic of China, Shanghai, PR China
3 shared publications- Jianping Jiang
Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA
2 shared publications Pei Li
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China
2 shared publicationsXiaogang Xu
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China
2 shared publications- Xiaogang Xu
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China
2 shared publications Xin Chen
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 18 May 2026
- Published by Springer Nature in BMC Microbiology
- Vol. 26 (1)
In vitro and in vivo activity of colistin-nitroxoline combination against polymyxin heteroresistant carbapenem-resistant Klebsiella pneumoniae
Carbapenem-resistant Klebsiella pneumoniae (CRKP) has emerged as a critical global health threat, often causing life-threatening infections with limited therapeutic options. Polymyxins are often used as the last-line agent, but its efficacy is limited by heteroresistance-where resistant subpopulations emerge during treatment. To combat this, we evaluated the synergistic activity of colistin combined with nitroxoline against polymyxin heteroresistant (PHR) CRKP subpopulations. The prevalence of PHR was 90.9% (10/11 isolates). While colistin or nitroxoline monotherapy failed to eradicate PHR subpopulations, the combination of colistin and nitroxoline achieved complete clearance at reduced concentrations in 3 out of 4 tested isolates. In adaptive laboratory evolution experiments, colistin monotherapy rapidly selected for resistant mutants, with MIC increasing 256-fold by the second passage. In contrast, the combination maintained stable susceptibility over 20 passages, with no detectable MIC increase. N-phenyl-1-naphthylamine and propidium iodide staining, along with scanning electron microscopy, revealed that the combination induced markedly enhanced membrane damage and cellular disruption compared to monotherapies. In a murine peritoneal infection model, combination therapy reduced mortality to 10% versus 30% with colistin monotherapy, although the difference was not statistically significant (p = 0.30). PHR is highly prevalent in CRKP and undermines colistin monotherapy. Colistin-nitroxoline combination exhibits potent synergy, suppresses resistance emergence, and shows promise for treating refractory CRKP infections.
- 18 May 2026
- Published by Springer Nature in BMC Microbiology
- Vol. 26 (1)
Open AccessIn vitro and in vivo activity of colistin-nitroxoline combination against polymyxin heteroresistant carbapenem-resistant Klebsiella pneumoniae
Carbapenem-resistant Klebsiella pneumoniae (CRKP) has emerged as a critical global health threat, often causing life-threatening infections with limited therapeutic options. Polymyxins are often used as the last-line agent, but its efficacy is limited by heteroresistance-where resistant subpopulations emerge during treatment. To combat this, we evaluated the synergistic activity of colistin combined with nitroxoline against polymyxin heteroresistant (PHR) CRKP subpopulations. The prevalence of PHR was 90.9% (10/11 isolates). While colistin or nitroxoline monotherapy failed to eradicate PHR subpopulations, the combination of colistin and nitroxoline achieved complete clearance at reduced concentrations in 3 out of 4 tested isolates. In adaptive laboratory evolution experiments, colistin monotherapy rapidly selected for resistant mutants, with MIC increasing 256-fold by the second passage. In contrast, the combination maintained stable susceptibility over 20 passages, with no detectable MIC increase. N-phenyl-1-naphthylamine and propidium iodide staining, along with scanning electron microscopy, revealed that the combination induced markedly enhanced membrane damage and cellular disruption compared to monotherapies. In a murine peritoneal infection model, combination therapy reduced mortality to 10% versus 30% with colistin monotherapy, although the difference was not statistically significant (p = 0.30). PHR is highly prevalent in CRKP and undermines colistin monotherapy. Colistin-nitroxoline combination exhibits potent synergy, suppresses resistance emergence, and shows promise for treating refractory CRKP infections.
- 18 January 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 65 (3) , 107445
The hidden threat: Klebsiella pneumoniae may develop co-resistance to colistin and cefiderocol under pressure of colistin
- 18 January 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 65 (3) , 107445
The hidden threat: Klebsiella pneumoniae may develop co-resistance to colistin and cefiderocol under pressure of colistin
- 17 January 2023
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 32, 196
Corrigendum to ‘Insertion sequence mediating mgrB disruption is the major mechanism of polymyxin resistance in carbapenem-resistant Klebsiella pneumoniae isolates from China’ [Journal of Global Antimicrobial Resistance 30 (2022) 357-362]
- 17 January 2023
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 32, 196
Corrigendum to ‘Insertion sequence mediating mgrB disruption is the major mechanism of polymyxin resistance in carbapenem-resistant Klebsiella pneumoniae isolates from China’ [Journal of Global Antimicrobial Resistance 30 (2022) 357-362]
- Open Access
- 8 July 2022
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 30, 357-362
Insertion sequence mediating mrgB disruption is the major mechanism of polymyxin resistance in carbapenem-resistant Klebsiella pneumoniae isolates from China
- 8 July 2022
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 30, 357-362
Open AccessInsertion sequence mediating mrgB disruption is the major mechanism of polymyxin resistance in carbapenem-resistant Klebsiella pneumoniae isolates from China